These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 2297484)

  • 21. A comparison of cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone (CMFVP) in patients with advanced breast cancer.
    Smalley RV; Lefante J; Bartolucci A; Carpenter J; Vogel C; Krauss S
    Breast Cancer Res Treat; 1983; 3(2):209-20. PubMed ID: 6688538
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sequential methotrexate and 5-FU in CMFP (cyclophosphamide, methotrexate, 5-FU, and prednisone) therapy for breast cancer.
    Cadman EC; Glick JH; Cross J; Horton J; Taylor SG
    Cancer Treat Rep; 1984 Jun; 68(6):877-9. PubMed ID: 6547367
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination chemotherapy for metastatic or recurrent carcinoma of the breast--a randomized phase III trial comparing CAF versus VATH versus VATH alternating with CMFVP: Cancer and Leukemia Group B Study 8281.
    Aisner J; Cirrincione C; Perloff M; Perry M; Budman D; Abrams J; Panasci L; Muss H; Citron M; Holland J
    J Clin Oncol; 1995 Jun; 13(6):1443-52. PubMed ID: 7751891
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: a randomized multinational study.
    Ackland SP; Anton A; Breitbach GP; Colajori E; Tursi JM; Delfino C; Efremidis A; Ezzat A; Fittipaldo A; Kolaric K; Lopez M; Viaro D;
    J Clin Oncol; 2001 Feb; 19(4):943-53. PubMed ID: 11181656
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-dose versus low-dose CMFP regimen in advanced breast cancer.
    Kumar A; Khanna NN; Pant GC; Khanna S
    J Surg Oncol; 1984 Apr; 25(4):300-2. PubMed ID: 6371385
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Postsurgical adjuvant chemotherapy of stage II breast carcinoma with or without crossover to a non-cross-resistant regimen: a Cancer and Leukemia Group B study.
    Perloff M; Norton L; Korzun AH; Wood WC; Carey RW; Gottlieb A; Aust JC; Bank A; Silver RT; Saleh F; Canellos GP; Perry MC; Weiss RB; Holland JF
    J Clin Oncol; 1996 May; 14(5):1589-98. PubMed ID: 8622076
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cyclophosphamide, methotrexate, and chronic oral tegafur modulated by folinic acid in the treatment of patients with advanced breast carcinoma.
    Ribas A; Albanell J; Solé-Calvo LA; Gallardo E; Bellmunt J; Vera R; Vidal R; Carulla J; Baselga J
    Cancer; 1998 Mar; 82(5):878-85. PubMed ID: 9486577
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adjuvant CMFVP versus adjuvant CMFVP plus ovariectomy for premenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study.
    Rivkin SE; Green S; O'Sullivan J; Cruz AB; Abeloff MD; Jewell WR; Costanzi JJ; Farrar WB; Osborne CK
    J Clin Oncol; 1996 Jan; 14(1):46-51. PubMed ID: 8558219
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chemotherapy of advanced breast cancer: a randomized trial of vincristine, Adriamycin, and cyclophosphamide (VAC) versus cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP).
    Carmo-Pereira J; Costa FO; Henriques E
    Cancer; 1981 Oct; 48(7):1517-21. PubMed ID: 7026020
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase II study of a dose-density regimen with fluorouracil, epirubicin, and cyclophosphamide on days 1 and 4 every 14 days with filgrastim support followed by weekly paclitaxel in women with primary breast cancer.
    Pietri E; Andreis D; Fabbri F; Menna C; Schirone A; Kopf B; Rocca A; Amadori D; De Giorgi U
    Oncologist; 2015 Mar; 20(3):239-40. PubMed ID: 25637379
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study.
    Rivkin SE; Green S; Metch B; Cruz AB; Abeloff MD; Jewell WR; Costanzi JJ; Farrar WB; Minton JP; Osborne CK
    J Clin Oncol; 1994 Oct; 12(10):2078-85. PubMed ID: 7931477
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An evaluation of the effect of vincristine added to cyclophosphamide, 5-fluorouracil, methotrexate, and prednisone in advanced breast cancer.
    Segaloff A; Hankey BF; Carter AC; Escher GC; Ansfield FJ; Talley RW
    Breast Cancer Res Treat; 1985; 5(3):311-9. PubMed ID: 3896353
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase II study.
    Gasparini G; Caffo O; Barni S; Frontini L; Testolin A; Guglielmi RB; Ambrosini G
    J Clin Oncol; 1994 Oct; 12(10):2094-101. PubMed ID: 7931479
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomized clinical trial of CFP versus CMFP in women with metastatic breast cancer.
    Marschke RF; Ingle JN; Schaid DJ; Krook JE; Mailliard JA; Cullinan SA; Pfeifle DM; Votava HJ; Ebbert LP; Windschitl HE
    Cancer; 1989 May; 63(10):1931-7. PubMed ID: 2649221
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of the CMFVP regimen in patients with metastatic breast cancer previously treated with anthracycline and taxane.
    Grenader T
    Onkologie; 2012; 35(1-2):24-6. PubMed ID: 22310341
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of Mega-COMLA (cyclophosphamide, cytarabine, vincristine, and methotrexate followed by leucovorin and prednisone) plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) in the treatment of lymphoid neoplasms with very poor prognosis.
    Hainsworth JD; Wolff SN; Stein RS; Greer JP; Cousar JB; Greco FA
    Cancer Treat Rep; 1986 Aug; 70(8):953-8. PubMed ID: 3015406
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized trial to compare the efficacy and toxicity of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with methotrexate mitoxantrone (MM) in advanced carcinoma of the breast.
    Harper-Wynne C; English J; Meyer L; Bower M; Archer C; Sinnett HD; Lowdell C; Coombes RC
    Br J Cancer; 1999 Sep; 81(2):316-22. PubMed ID: 10496359
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Higher average received relative dose intensities of cyclophosphamide, methotrexate and 5-fluorouracil using a 24-hour method: implications for improved cure rates in breast cancer.
    Price LA; Hill BT
    Cancer Treat Rev; 1990 Sep; 17(2-3):191-6. PubMed ID: 2272033
    [No Abstract]   [Full Text] [Related]  

  • 39. High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: a prospective randomized italian multicenter study.
    Martelli M; Vignetti M; Zinzani PL; Gherlinzoni F; Meloni G; Fiacchini M; De Sanctis V; Papa G; Martelli MF; Calabresi F; Tura S; Mandelli F
    J Clin Oncol; 1996 Feb; 14(2):534-42. PubMed ID: 8636768
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomised comparative trial of mitozantrone/methotrexate/mitomycin C (MMM) and cyclophosphamide/methotrexate/5 FU (CMF) in the treatment of advanced breast cancer.
    Jodrell DI; Smith IE; Mansi JL; Pearson MC; Walsh G; Ashley S; Sinnett HD; McKinna JA
    Br J Cancer; 1991 May; 63(5):794-8. PubMed ID: 2039705
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.